Table 2 Patient demographics in Bevacizumab qPCR and Control sets
Variable | Set | |||
|---|---|---|---|---|
Control | Bev qPCR | P-value | ||
Patients | N | 72 | 49 | |
Age | Median | 64.5 | 60.1 | 0.0543 |
Range | 41-77 | 32-77 | ||
N (%) | N (%) | |||
Chemotherapy | ||||
Irinotecan-based regimen | 42 (58.3) | 23 (46.9) | 0.1084 | |
Oxaliplatin-based regimen | 16 (22.2) | 21 (42.9) | ||
Both irinotecan and oxaliplatin | 5 (6.9) | 1 (2.0) | ||
Fluoropyrimidine only | 2 (2.8) | 2 (4.1) | ||
Erbitux only | 7 (9.7) | 2 (4.1) | ||
Best response | CR | 5 (6.9) | 1 (2.0) | 0.5364 |
PR | 26 (36.1) | 17 (34.7) | ||
SD | 16 (22.2) | 14 (28.6) | ||
PD | 9 (12.5) | 10 (20.4) | ||
NE/Missing Data | 16 (22.3) | 7 (14.3) | ||
Histological grade | 1-2 | 50 (69.4) | 34 (69.4) | 0.8638 |
3-4 | 19 (26.4) | 12 (24.4) | ||
Primary site | Left | 54 (75.0) | 35 (71.4) | 0.6619 |
Right | 18 (25.0) | 14 (28.6) | ||
Gender | Female | 24 (33.3) | 24 (49.0) | 0.0842 |
Male | 48 (66.7) | 25 (51.0) | ||
Stage at biopsy | I-III | 25 (34.8) | 16 (32.6) | 0.8962 |
IV | 46 (63.8) | 31 (63.2) | ||
8-month progression-free rate | 39 (54.2) | 25 (51.0) | 0.6352 | |
Metastasectomy | 6 (8.3) | 7 (14.3) | 0.5480 | |